Literature DB >> 21308523

Clinical Trials Report: Progress Toward an Effective Malaria Vaccine: RTS,S/ASO1B and RTS,S/ASO2A.

Lin H Chen1.   

Abstract

Entities:  

Year:  2010        PMID： 21308523     DOI： 10.1007/s11908-010-0117-0

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


× No keyword cloud information.
  9 in total

1.  Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

Authors:  Peifang Sun; Robert Schwenk; Katherine White; Jose A Stoute; Joe Cohen; W Ripley Ballou; Gerald Voss; Kent E Kester; D Gray Heppner; Urszula Krzych
Journal:  J Immunol       Date:  2003-12-15       Impact factor: 5.422

Review 2.  Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant.

Authors:  Nathalie Garçon; D Gray Heppner; Joe Cohen
Journal:  Expert Rev Vaccines       Date:  2003-04       Impact factor: 5.217

3.  Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.

Authors:  Kalifa A Bojang; Folasade Olodude; Margaret Pinder; Opokua Ofori-Anyinam; Laurence Vigneron; Steve Fitzpatrick; Fanta Njie; Adams Kassanga; Amanda Leach; Jessica Milman; Regina Rabinovich; Keith P W J McAdam; Kent E Kester; D Gray Heppner; Joe D Cohen; Nadia Tornieporth; Paul J M Milligan
Journal:  Vaccine       Date:  2005-04-15       Impact factor: 3.641

4.  Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya.

Authors:  José A Stoute; D Gray Heppner; Carl J Mason; Joram Siangla; Malachi O Opollo; Kent E Kester; Laurence Vigneron; Gerald Voss; Michael J Walter; Nadia Tornieporth; Joe D Cohen; W Ripley Ballou
Journal:  Am J Trop Med Hyg       Date:  2006-07       Impact factor: 2.345

5.  Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.

Authors:  E Macete; J J Aponte; C Guinovart; J Sacarlal; O Ofori-Anyinam; I Mandomando; M Espasa; C Bevilacqua; A Leach; M C Dubois; D G Heppner; L Tello; J Milman; J Cohen; F Dubovsky; N Tornieporth; R Thompson; P L Alonso
Journal:  Trop Med Int Health       Date:  2007-01       Impact factor: 2.622

6.  Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.

Authors:  Jahit Sacarlal; Pedro Aide; John J Aponte; Montse Renom; Amanda Leach; Inácio Mandomando; Marc Lievens; Quique Bassat; Sarah Lafuente; Eusébio Macete; Johan Vekemans; Caterina Guinovart; Betuel Sigaúque; Marla Sillman; Jessica Milman; Marie-Claude Dubois; Marie-Ange Demoitié; Joelle Thonnard; Clara Menéndez; W Ripley Ballou; Joe Cohen; Pedro L Alonso
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226

7.  Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.

Authors:  Pedro L Alonso; Jahit Sacarlal; John J Aponte; Amanda Leach; Eusebio Macete; Pedro Aide; Betuel Sigauque; Jessica Milman; Inacio Mandomando; Quique Bassat; Caterina Guinovart; Mateu Espasa; Sabine Corachan; Marc Lievens; Margarita M Navia; Marie-Claude Dubois; Clara Menendez; Filip Dubovsky; Joe Cohen; Ricardo Thompson; W Ripley Ballou
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321

Review 8.  The development of the RTS,S malaria vaccine candidate: challenges and lessons.

Authors:  W R Ballou
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

9.  Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.

Authors:  Mark E Polhemus; Shon A Remich; Bernhards R Ogutu; John N Waitumbi; Lucas Otieno; Stella Apollo; James F Cummings; Kent E Kester; Christian F Ockenhouse; Ann Stewart; Opokua Ofori-Anyinam; Isabelle Ramboer; Conor P Cahill; Marc Lievens; Marie-Claude Dubois; Marie-Ange Demoitie; Amanda Leach; Joe Cohen; W Ripley Ballou; D Gray Heppner
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.